United States / USD Country & Currency
Country
United States
Currency
US Dollars
Save
Country
Australia
Gibraltar
Hong Kong
Malta
Northern Ireland
Puerto Rico
Scotland
Singapore
Switzerland
United Kingdom
United States
Currency
US Dollars
GB Pounds
AU Dollars
Euro
Explore our range Categories
Ask us a question 877-271-6591 or 800-868-9064
ATTENTION: ALL CUSTOMERS

The Vanuatu Government has declared a state of emergency after a violent earthquake struck Vanuatu’s capital, Port Vila, on Tuesday, where we are located. All network, communication services and cargo flights are impacted.

Our priority is to ensure all our staff and families are safe, as is our workplace environment, before returning. We will endeavour to provide you with updates on the developing situation and hope to have operations commence as swiftly as possible and when it is safe to do as advised by the Vanuatu Government. We appreciate your patience, support and understanding through this challenging time.

Shipping delays due to Covid-19 Virus

Please fill the form to receive updates when we can ship your order.

Progestins

Our Progestins class of Transgender products contain various forms of the female hormone progesterone. Synthetic progestins and progestogens such as progesterone Endogest Progestin or Provera are used in a feminizing regimen for transgender hormone therapy during a gender reassignment programme. 

What are progestins and progestogens?

Progesterone is the female hormone that in women prepares the endometrium (lining of the uterus) for a potential pregnancy.  Progestogens have the same biological activity as naturally occurring progesterone but the chemical structure has been slightly altered to improve stability and absorption. Progestins are synthetic progestogens that have a different chemical structure to progesterone but similar biological effects. 

Progestins and progestogens are used medically for contraception, hormone replacement therapy in menopausal women and to treat certain conditions like endometriosis.  

Use of progestins and progestogens for transgender hormone therapy

Although the clinical opinion is mixed on their effectiveness of use, progestins and progestogens can be used as part of the feminization regime for male to female transgender hormone therapy1.  The rational for this is that adding progesterone in some form more closely simulates the female hormone cycle.  However, there are also some side effects including, weight gain, oedema, and mood swings.  There is also an increased risk of developing breast cancer2.

Progesterone suppresses testosterone production and is also thought to support breast development in transgender hormone therapy, which is one of the roles of progesterone in females.  Although oestrogen is primarily responsible for breast development in females, progesterone is involved in regulation the growth and differentiation of breast tissue.  Also during pregnancy, progesterone contributes to increasing the size of breasts and the nipples in preparation for lactation. 

Progestin products

Progestins, which are synthetic progestogens, available are:

  • Medroxyprogesterone
  • Hydroxyprogesterone
  • Dydrogesterone
Medroxyprogesterone and hydroxyprogesterone are both administered by injection and are more potent and longer-acting than natural progesterone. Medroxyprogesterone is also available for oral administration as is dydrogesterone.  Progestins are more active when taken orally than natural progesterone and do not have other hormonal effects.

Progestogen products

Micronized progesterone, in which natural progesterone is reduced to tiny particles for better absorption, is available as a gel and as capsules.

Progesterone is also available for injection in an oil base for stability. 

References

  1. Wierckx K, Gooren L, T'Sjoen G. Clinical review: Breast development in trans women receiving cross-sex hormones. J Sex Med 2014 May;11(5):1240-7
  2. Axlund SD, Sartorius CA. Progesterone regulation of stem and progenitor cells in normal and malignant breast. Mol Cell Endocrinol 2012 Jun 24;357(1-2):71-9. 



Read more
 

This website uses cookies. View our policy and select your preferences here